Nanozymes: Gold Nanoparticle‑Based RNA Cleavage for Gene Silencing

Nanozymes: Gold Nanoparticle‑Based RNA Cleavage for Gene Silencing

A nanozyme is a gold nanoparticle conjugated with an endoribonuclease and a DNA strand that is complementary to a specific RNA target. When the DNA‑RNA hybrid forms, the endonuclease cleaves the RNA at a precise site, mimicking the natural RNA‑induced silencing complex (RISC) that operates in RNA interference (RNAi) pathways.

Developed by researchers at the University of Florida’s Cao Research Group, nanozymes aim to overcome key limitations of siRNA therapeutics. By leveraging the inherent stability of gold nanoparticles, these constructs remain active longer, exhibit reduced immunogenicity, and show minimal cytotoxicity compared to traditional RNAi agents.

• Antiviral activity – Nanozymes can enter virus‑infected cells, target viral RNAs such as HCV, and suppress viral protein synthesis, thereby limiting replication without harming host cells.
• Tissue‑specific delivery – Functionalizing the nanoparticle surface with targeting ligands allows selective accumulation in tumors or organs (e.g., liver), enhancing therapeutic precision.
• Gene‑expression control – Beyond viral targets, nanozymes can silence disease‑associated genes in vitro and in vivo, offering a versatile platform for treating genetic disorders.
• Safety profile – Studies indicate that nanozymes do not elicit overt toxicity in cultured cells, making them promising candidates for clinical translation.

Current research is evaluating nanozyme fidelity in the presence of DNA/RNA mismatches and monitoring cytokine induction to ensure immunological safety. The modular design also enables subcellular targeting, opening avenues for precision medicine.